Sharon A. Lobert
PROFESSOR EMERITUS
Education
| Vanderbilt University, PhD, Molecular Biology | 1989 |
| Vanderbilt University, MSN, Nurse Practitioner | 1979 |
| Tennessee State University, AD, Nursing | 1976 |
| University of Michigan Ann Arbor, BA, Comparative Literature | 1972 |
Specialty Certification Licensure
| Licensure, RN |
Current Positions
| Associate Dean, School of Nursing | 04/2006 - Present |
| The University of Mississippi Medical Center Jackson, Mississippi 39216 | |
Academic Appointments or Other Previous Appointments
| Assistant Dean, School of Nursing | 09/2003 - 03/2006 |
| MSN Program Director, School of Nursing | 03/2002 - 08/2003 |
| School of Nursing, Office Of The Dean Medical School |
Sponsored Program Funding
| Extramural, Statewide consortium outreach model for delivery of DNP education, HrSA | 07/2011 - 06/2014 |
| Intramural, Validation of biomarkers for head and neck squamous cell carcinoma, UMMC | 11/2009 - 10/2010 |
| Extramural, Systems biology of antimitotic drugs and chemotherapy, carraway Foundation | 06/2007 - 05/2008 |
| Extramural, Protection against neurotoxicity, Carraway Foundation | 07/2006 - 06/2007 |
| Extramural, Efficacy of neuroprotective agents in myelinated neuronal cell culture, Southeastern center for emerging biologic threats | 07/2005 - 06/2006 |
| Extramural, Biomarkers for aggressive lung carcinomas in African American men, DOD | 07/2004 - 06/2007 |
| Extramural, Structural drug receptor changes in combination chemotherapy, Oncology Nursing Foundation | 05/2000 - 05/2002 |
| Extramural, Sedimentation velocity and microtubule inhibition of vinca alkaloid analogs and tubulin, Pierre Fabre | 10/1998 - 04/1999 |
| Extramural, Predictors of vinca alkaloid pharmacokinetics, NIH | 09/1998 - 08/2001 |
| Extramural, Interaction of Antimitotics with Tubulin Isotypes, NIH | 09/1998 - 08/2001 |
| Extramural, Dilantin enhancement of vinca alkaloid cytotoxicity, Oncology Nursing Foundation/Bristol Myers Squibb | 01/1998 - 12/1999 |
| Extramural, Preclinical investigations of a novel vinca alkaloid, Pierre Fabre | 11/1996 - 10/1996 |
| Extramural, Predictors of Vinca Alkaloid Pharmacokinetics, NIH | 09/1992 - 08/1997 |
Presentations
| Poster Presentation, Paclitaxel treatment of MDA-MB-231 breast cancer cells stabilizes cytoplasmic p27Kip1 and reduces total intracellular stathmin, American Society for Cell Biology, San Francisco, CA | 12/2016 |
| Poster Presentation, Effect of low dose paclitaxel treatment on β-tubulin isotype distribution and non-tubulin targets in breast cancer cells, International Meeting on Microtubules/EMBL, Heidelberg Germany | 05/2016 |
| Poster Presentation, Low dose paclitaxel increases the tability of p27kip1, AACR-NCI-EORTC, Boston MA | 11/2015 |
| Poster Presentation, Prognostic biomarkers for HNSCC: β-tubulin isotypes and the p53 interactome, ASCB, Philadelphia | 12/2014 |
| Poster Presentation, Paclitaxel induces changes in beta tubulin isotypes and epithelial to mesenchymal transition protein ZEB1 in breast cancer cells, American Society for Cell Biology | 12/2013 |